Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 8/20 | 0.35 |
| ▸ | KAT5 | Q92993 | 6/20 | 0.35 |
| ▸ | KAT8 | Q9H7Z6 | 13/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23713286 | 0.89 | NTRK1 (0.41) | KAT6AKAT5KAT8NTRK1KCNH2 | |
| SCHEMBL23698796 | 0.89 | KAT6A (0.36) | KAT6AKAT5KAT8NTRK1CHRM1 | |
| SCHEMBL23698891 | 0.88 | BRD4 (0.36) | KAT6AKAT5CHRM1 | |
| SCHEMBL23698817 | 0.85 | CHRM1 (0.47) | CHRM1 | |
| SCHEMBL23698798 | 0.82 | CHRM1 (0.49) | CHRM1 | |
| SCHEMBL21834493 | 0.81 | CHRM1 (0.44) | CHRM1 | |
| SCHEMBL21834480 | 0.81 | CHRM1 (0.58) | CHRM1 | |
| SCHEMBL23698806 | 0.78 | CD74 (0.37) | — | |
| SCHEMBL23698815 | 0.78 | CHRM1 (0.47) | CHRM1 | |
| SCHEMBL23698855 | 0.77 | BRD4 (0.35) | KAT6AKAT5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162864-B2 | Condensed-cyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-12-10 | — | — | US | disclosed |
| EP-3858823-A1 | CONDENSED-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020067457-A1 | CONDENSED-CYCLIC COMPOUND | 武田薬品工業株式会社 | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162864-B2 | Condensed-cyclic compound | SLC10A2, VIP, AVPR2 | KAT6A 1717/4885KAT5 586/4885KAT8 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.